Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- AKTS
- Price
- 22.40
- Stock movement up
- +2.00 (9.80%)
- Company name
- Aktis Oncology, Inc. Common stock
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.13B
- Ent value
- 1.37B
- Price/Sales
- 113.91
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 11.53%
- 1 year return (CAGR)
- -
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
AKTS does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 113.91 |
| Price to Book | - |
| EV to Sales | 137.12 |
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 50.65M |
| EPS (TTM) | - |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 9.96M |
| Gross profit (TTM) | 4.30M |
| Operating income (TTM) | -20.97M |
| Net income (TTM) | -18.48M |
| EPS (TTM) | - |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | 43.19% |
| Operating margin (TTM) | -210.55% |
| Profit margin (TTM) | -185.50% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 180.25M |
| Net receivables | 0.00 |
| Total current assets | 249.42M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 29.15M |
| Total assets | 279.04M |
| Accounts payable | 2.36M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 26.91M |
| Total liabilities | 411.43M |
| Shareholder's equity | -132.39M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -25.00M |
| Capital expenditures (TTM) | 2.36M |
| Free cash flow (TTM) | -35.47M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -6.62% |
| Return on Invested Capital | 13.96% |
| Cash Return on Invested Capital | 26.79% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 20.41 |
| Daily high | 23.36 |
| Daily low | 20.04 |
| Daily Volume | 432K |
| All-time high | 22.40 |
| 1y analyst estimate | - |
| Beta | - |
| EPS (TTM) | - |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| AKTS | S&P500 | |
| Current price drop from All-time high | -16.21% | -2.53% |
| Highest price drop | -99.97% | -19.00% |
| Date of highest drop | 18 Dec 2024 | 8 Apr 2025 |
| Avg drop from high | -85.44% | -2.49% |
| Avg time to new high | 30 days | 6 days |
| Max time to new high | 50 days | 89 days |
COMPANY DETAILS
Marketcap
1.13B
Marketcap category
Small-cap
Description
Aktis Oncology, Inc. operates as a clinical-stage oncology company that engages in the development of targeted radiopharmaceutical therapies for cancer treatment. The company offers a miniprotein radioconjugate platform to discover and develop radiopharmaceutical therapies that deliver the tumor-killing properties of radioisotopes. It offers Nectin-4, a miniprotein radioconjugate for the treatment of locally advanced or metastatic urothelial cancer. Its products include AKY-1189 to deliver a radioisotope to Nectin-4 expressing tumors for the treatment of metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and AKY-2519 to deliver radioisotope to B7-H3 CD276 expressing tumors targeting prostate, lung and other solid tumors. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is based in Boston, Massachusetts.
Employees
Investor relations
-
SEC filings
CEO
Jeffrey B. Shealy
Country
USA
City
Huntersville
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner